Clinical Research Details

AMG 423 20110203: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction

Study Description

to evaluate the effect of treatment with omecamtiv mecarbil (OM) compared with placebo on the time to cardiovascular (CV) death or first HF event, whichever occurs first, in subjects with chronic HF with reduced ejection fraction (HFrEF) receiving standard of care (SoC) therapy

Subjects will be randomized to study drug or placebo.

Open Enrollment

Contact Name: Andrea Goosen
Contact Phone: (904) 244-5617
Contact Email:


Principal Investigator
Fabiana Rollini, M.B.Ch.B. (M.D.)

Sub Investigator
Francesco Franchi, M.B.Ch.B. (M.D.)